Pre-surgery immunotherapy for early-stage liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new dual immunotherapy drug (QL1706) given before surgery to remove liver cancer. The goal is to reduce the chance the cancer comes back after surgery in patients with early-stage disease that has high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with primary hepatocellular carcinoma (liver cancer) that can be surgically removed
- Stage IB or IIA disease with high recurrence risk (specific tumor size/number requirements)
- Age 18–75 with good overall health (ECOG score 0–1) and normal liver function (Child-Pugh Grade A)
- No prior chemotherapy, radiation, or immunotherapy treatments
- No other active cancers (except treated skin cancer or cervical pre-cancer)
- Able to use effective contraception if of childbearing age; willing to follow up with study team
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (bevacizumab) after surgery or ablation for liver cancer that has a high chance of coming back. The goal is to see if this treatment can reduce the risk of recurrence.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.
This trial tests two drugs given before surgery to people with liver cancer that has a high chance of coming back. The goal is to see if the drugs can shrink the tumor and lower the risk of recurrence.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
Hear when a new Iparomlimab and Tuvonralimab Injection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.